 | Up a level |
2017
Mazieres, J., Novello, S., De Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Wolf, J., Zeaiter, A., Cardona, A., Balas, B., Karagiannis, T., Chlistalla, M., Smoljanovic, V. and Oh, I. (2017). Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC. J. Thorac. Oncol., 12 (11). S. S1897 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
de Castro, J., Novello, S., Mazieres, J., Oh, I-J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., de Marinis, F., Zeaiter, A., Cardona, A., Balas, B., Johannsdottir, H., Chlistalla, M., Smoljanovic, V. and Wolf, J. (2017). CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK plus NSCLC. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041